187 related articles for article (PubMed ID: 23696924)
21. Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.
Le M; Garcilazo Y; Ibáñez-Juliá MJ; Younan N; Royer-Perron L; Benazra M; Mokhtari K; Houillier C; Hoang-Xuan K; Alentorn A
Oncologist; 2019 Sep; 24(9):e898-e904. PubMed ID: 30867243
[TBL] [Abstract][Full Text] [Related]
22. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
[TBL] [Abstract][Full Text] [Related]
23. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.
Wu S; Wang J; Liu W; Hu F; Zhao K; Jiang W; Lei T; Shu K
BMC Neurol; 2021 May; 21(1):190. PubMed ID: 33975554
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis.
Kaulen LD; Karschnia P; Dietrich J; Baehring JM
J Neurooncol; 2020 Aug; 149(1):153-159. PubMed ID: 32683530
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review).
Liu Y; Yao Q; Zhang F
Int J Oncol; 2021 Mar; 58(3):371-387. PubMed ID: 33650642
[TBL] [Abstract][Full Text] [Related]
26. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
[TBL] [Abstract][Full Text] [Related]
27. Survival among patients with primary central nervous system lymphoma, 1973-2004.
Norden AD; Drappatz J; Wen PY; Claus EB
J Neurooncol; 2011 Feb; 101(3):487-93. PubMed ID: 20556477
[TBL] [Abstract][Full Text] [Related]
28. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.
Chamberlain MC
J Neurooncol; 2013 May; 113(1):27-32. PubMed ID: 23456654
[TBL] [Abstract][Full Text] [Related]
29. Atypical presentation of primary central nervous system non-Hodgkin lymphoma in immunocompetent young adults.
Cheatle JT; Aizenberg MR; Weinberg JS; Surdell DL
World Neurosurg; 2013; 79(3-4):593.e9-13. PubMed ID: 22885166
[TBL] [Abstract][Full Text] [Related]
30. Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.
Fleury I; Amorim S; Mounier N; Coiffier B; Dupuis J; Tilly H; Mazari MA; Filliatre L; Brière J; Brice P; de Kerviler E; Thieblemont C
Leuk Lymphoma; 2015 Jul; 56(7):2025-31. PubMed ID: 25347431
[TBL] [Abstract][Full Text] [Related]
31. [Different treatment regimens for primary central nervous system lymphoma:based on SEER database].
Yang CW; Ren XH; Jiang HH; Li MX; Zhao XZ; Zhu QH; Cui Y; Lin S
Zhonghua Wai Ke Za Zhi; 2021 Jan; 59(1):52-58. PubMed ID: 33412634
[No Abstract] [Full Text] [Related]
32. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Grimm SA; Pulido JS; Jahnke K; Schiff D; Hall AJ; Shenkier TN; Siegal T; Doolittle ND; Batchelor T; Herrlinger U; Neuwelt EA; Laperriere N; Chamberlain MC; Blay JY; Ferreri AJ; Omuro AM; Thiel E; Abrey LE
Ann Oncol; 2007 Nov; 18(11):1851-5. PubMed ID: 17804469
[TBL] [Abstract][Full Text] [Related]
33. The role of surgery in primary central nervous system lymphomas.
Villalonga JF; Alessandro L; Farez MF; Mormandi R; Cervio A; Alcorta SC; Muggeri A
Arq Neuropsiquiatr; 2018 Mar; 76(3):139-144. PubMed ID: 29809232
[TBL] [Abstract][Full Text] [Related]
34. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.
Bayraktar S; Bayraktar UD; Ramos JC; Stefanovic A; Lossos IS
J Neurooncol; 2011 Jan; 101(2):257-65. PubMed ID: 20526793
[TBL] [Abstract][Full Text] [Related]
35. Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.
Park JS; Lim DH; Ahn YC; Park W; Kim SJ; Kim WS; Kim K
Jpn J Clin Oncol; 2017 Nov; 47(11):995-1001. PubMed ID: 28973509
[TBL] [Abstract][Full Text] [Related]
36. Significance of treatment response when managing patients with primary central nervous system lymphoma.
Chan H; Moraes FY; Berlin A; Crump M; Mason W; Laperriere N; Kuruvilla J; Prica A
Leuk Lymphoma; 2019 Feb; 60(2):349-357. PubMed ID: 29966463
[TBL] [Abstract][Full Text] [Related]
37. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
[TBL] [Abstract][Full Text] [Related]
38. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.
Zhang Y; Zhang Q; Wang XX; Deng XF; Zhu YZ
Clin Radiol; 2016 Oct; 71(10):1018-1029. PubMed ID: 27341986
[TBL] [Abstract][Full Text] [Related]
39. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
40. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
